In addition to the ongoing negotiations for RSA renewal, an insurance benefit standard will be newly established for ‘Lynparza (olaparib)’ as maintenance monotherapy.

The Health Insurance Review and Assessment Service (HIRA) has announced that it has posted a public notice on the ‘Details of the standards and methods for applying insurance benefit to pharmaceuticals prescribed or administered to cancer patients,’ and will be reviewing opinions until the 27th. The amended details will be effective from October 1st.

After reviewing the reimbursement standards for Lynparza in ovarian cancer, HIRA decided to allow its reimbursement as ‘first-line maintenance treatment for patients newly